Resources
Education by default. Each guide and piece of commentary is meant to make you a sharper investor on the next decision, platform walkthroughs, market notes, and frameworks you can apply with or without Finapolis.
Macro analysis and market commentary from our research team
Featured
Market Commentary
Midyear outlook: a hot earnings cycle meets a more hawkish Fed
Where US equities and the macro sit at midyear 2026: 84% Q1 beats, ~21x forward P/E, 3.8% CPI, the 10-year at 4.49%, and a new Fed Chair.
Danaher's bioprocessing cycle is turning. How much is already in the price?
Danaher trades near a 52-week low as bioprocessing orders turn up and the $9.9B Masimo deal lands. We line up price, the DCF, and the platform target.
GoDaddy after a 50% drawdown: reading the gap between price and the cash-flow model
GoDaddy has fallen by half while free cash flow rose. A grounded look at the gap between an $84 price and a $124 DCF.
First Solar at a new high: what the numbers say, and what they leave to you
First Solar trades above its Finapolis target and DCF value, yet its P/E sits below its 5-year median as a 45X tax credit underwrites earnings.
All Articles
Every article we have published, newest first
The Finapolis Portfolio page, tab by tab
A guide to the Finapolis Portfolio page: the 5 summary cards, and what each of the 8 tabs is for, including the Modified Dietz monthly returns table that prints the denominator behind every percentage.
A beta of 0.61 and a beta of 2.75: reading risk numbers against a benchmark
What the 4 portfolio risk numbers measure, shown on 2 real portfolios with opposite profiles, and why a low beta does not mean safer and a high Sharpe does not mean comfortable.
From 5,957 stocks to 26: what a quality screen is actually claiming
How 10 conditions cut a 5,957-stock universe to 26, what each threshold rules out, and why what a screen excludes matters as much as what it returns.
How Finapolis grades a stock: reading the Analyzer Score Card
How the Finapolis Analyzer grades a stock A to D on fundamentals, technicals and health, how the three roll into one grade, and why its target price and DCF can disagree.
Discounted cash flow (DCF) valuation: method, limitations, and a Philip Morris example
How a discounted cash flow (DCF) valuation is built — its strengths, limits, the two terminal-value methods, and a worked Philip Morris example.
Best stock research platform in 2026: Finapolis vs Finviz vs Koyfin vs Fiscal.ai
Finviz, Koyfin, Fiscal.ai, or Finapolis? An honest 2026 read on what each does best — with real screenshots, pricing, and who each fits.
Fiscal.ai vs Finapolis: a Fiscal.ai alternative with options and tax tools (2026)
Fiscal.ai is strong, cheap AI research with global data. See what it leaves out, and how Finapolis adds grades, sourced reports, options, and portfolio.
Koyfin vs Finapolis: a Koyfin alternative that takes a position (2026)
Koyfin is a superb data terminal. See what it leaves to you, and how Finapolis grades, values, and writes sourced research on top of the data. 2026 comparison.
Finviz vs Finapolis: a fundamentals-first Finviz alternative (2026)
Finviz is the best free stock screener. See what happens after the screen, and how Finapolis grades, values, and researches the names you find. 2026 comparison.
Guides Tailored to Your Role
Find resources specifically designed for how you use Finapolis
Self-directed investors
You pick your own stocks and want real research behind every call.
Tax-aware DIY investors
You manage your own portfolio and sweat the details: valuation, options, and tax timing.
Boutique investment firms
A small team running its own internal research, without an institutional price tag.
Transforming fragmented data into investment conviction
Start your 14-day free trial. No credit card required.